Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

诱导多能干细胞（iPSC）能再分化成特定的细胞类型、组织和器官，联合基因编辑技术使用，可用于探索疾病发生的机制、开发新型有效的药物和细胞 ...

诱导多能干细胞（iPSC）能再分化成特定的细胞类型、组织和器官，联合基因编辑技术使用，可用于探索疾病发生的机制、开发新型有效的药物和细胞治疗等。赛业生物iPSC体外技术服务平台，拥有成熟的重编程、基因编辑和体外分化技术，同时结合一站式表型 ...

五、针对下游应用优化关键PIVs 拟胚体（EB）的大小和密度（每毫升EB数）是iPSC聚集体分化为自然杀伤（NK）免疫细胞的关键工艺输入变量（PIVs）。虽然目前尚未确定从iPSC EBs生成NK细胞的最佳EB大小和密度，但这些PIVs可以通过调整生物反应器的搅拌速率（流体 ...

FATE uses its platform with iPSC technology that can create reprogrammed stem cells. In turn, these specially designed stem cells can produce all kinds of human cells, including T and NK cells.

Methods: Here, we employ RPE cells derived from induced pluripotent stem cells (iPSC) generated from donors, carrying either homozygous 402Y (low risk) or 402H (high risk) variants of the CFH gene.

Ukrainian troops then crossed the Russian border in August in a shock incursion into the region of Kursk, seizing around 500 sq miles. It’s thought North Korea subsequently offered up its troops ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...